Research programme: hepatitis C therapeutics - Dynavax

Drug Profile

Research programme: hepatitis C therapeutics - Dynavax

Alternative Names: Hepatitis C immunostimulatory DNA therapy

Latest Information Update: 18 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dynavax Technologies
  • Developer Dynavax Technologies; Symphony Dynamo
  • Class Oligonucleotides
  • Mechanism of Action Th1 cell stimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 18 Apr 2012 No development reported - Preclinical for Hepatitis C in USA (unspecified route)
  • 16 Apr 2008 Preclinical trials in Hepatitis C in USA (unspecified route)
  • 26 Sep 2006 Early research in Hepatitis C in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top